Hib-DTaP-poliovirus vaccine - Sanofi Pasteur

Drug Profile

Hib-DTaP-poliovirus vaccine - Sanofi Pasteur

Alternative Names: DTaP-IPV-Hib - sanofi pasteur; Hib-DTP-acellular-poliovirus vaccine - sanofi pasteur; Pediacel; Pentacel; Pentaxim; SP 0204; VN 0105

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator sanofi pasteur
  • Developer Kitasato Daiichi Sankyo Vaccine; Sanofi Pasteur
  • Class Haemophilus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

  • 02 Jan 2017 Sanofi Pasteur MSD ended their joint venture and will separately pursue their vaccine strategies in Europe
  • 01 Oct 2014 Phase-III clinical trials in Tetanus, Poliomyelitis, Pertusis, Haemophilus infections, Diphtheria (In children, In infants, Prevention) in Japan (SC) (NCT02274285)
  • 30 Apr 2012 Final immunogenicity data from a Phase-III trial in Diphtheria, Haemophilus infections, Pertussis, Poliomyelitis and Tetanus (in infants, prevention) released by sanofi pasteur
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top